A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Patients With Elevated Intraocular Pressure

Trial Profile

A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Patients With Elevated Intraocular Pressure

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Latanoprost/netarsudil (Primary) ; Latanoprost; Netarsudil
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 14 Jul 2014 Primary endpoint 'Intraocular pressure (The mean diurnal IOP across subjects within the treatment group) has been met according to an Aerie Pharmaceuticals media release.
    • 26 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Jun 2014 Results published in the Aerie Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top